A gene therapy-based factor VIIa (FVIIa) given as prophylactic, or preventative, treatment was seen to produce specific factor levels needed to reduce the frequency of spontaneous bleeding episodes in a rat model of hemophilia A. According to scientists, this work may be a first step in developing therapies that…
To help people understand the science behind hemophilia and other bleeding disorders, digital content agency Believe Limited will present its first science fair this fall. Sponsored by commercial gene therapy company Spark Therapeutics, the science fair will be held at the National Hemophilia Foundation’s 71st Bleeding Disorders Conference…
Doctors in Canada are proposing a set of measures to better judge outcomes and the success of programs helping teen-age hemophilia patients transition to adult care, especially for those with more severe disease. They also listed 15 “key elements” of a successful pediatric-to-adult transition program, including eight the doctors saw as feasible…
A combination of Cyklokapron and Feiba — usually avoided due to a perceived risk of blood clots — appears to be safe and effective for treating patients with acquired hemophilia A (AHA), though these early study results need to be confirmed in clinical trials, researchers in Italy say. The study, “…
Recognizing risk factors of thrombosis and carefully monitoring medication doses are crucial for minimizing thrombotic complications in older patients with acquired hemophilia and serious illnesses like cardiovascular disease, a report describing four cases says. The study, “Acquired Haemophilia A. Which is the best therapeutic choice in older adults? Single…
In recognition of World Hemophilia Day (WHD), Catalyst Biosciences is hosting an “Ask Me Anything” (AMA) session on Reddit on April 17. During the Reddit AMA event, which will take place at noon EST Wednesday, clinicians will answer questions from patients and caregivers about bleeding disorders including hemophilia. A…
Fewer HIV infections and better care may explain the higher prevalence of hemophilia in male patients in Indiana between 2011 and 2013 than previously reported in six other states, according to a new study. The findings also revealed a higher utilization of Hemophilia Treatment Centers (HTCs) by this patient…
The remarkable journey of Chris Bombardier, the first hemophiliac to reach the pinnacle of Mount Everest and the Seven Summits, will be shown in a free screening April 14 in New York City. Sponsored by Octapharma USA, the documentary “Bombardier Blood” will be presented by the…
Bleeding episodes, chronic pain, and the presence of inhibitors in children with hemophilia cause emotional stress for caregivers and increase their burden, according to an European study that recommended early access to support services. Caring for a child with hemophilia, particularly when coping with poor joint health, leads to emotional stress,…
Catalyst Biosciences announced the beginning of enrollment for a Phase 2b clinical trial for dalcinonacog alfa (DalcA) in people with Hemophilia B. Hemophilia B is caused by the lack of a functional Factor IX clotting protein. Like many available therapeutics for Hemophila B, DalcA is essentially a lab-manufactured version…
Get regular updates to your inbox.
